GlassScriptPhysician profile
Douglas J Glod
NPI 1851470595
$73,573.39
in general payments reported to CMS, 2019-2025
32 companies · $687 in 2025
The $687 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $4,146 · 2021: $41K · 2022: $6,539 · 2023: $3,478 · 2024: $318 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,550 · Food and Beverage: $1,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,550.00 |
| Food and Beverage | $1,933.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medshape, INC. | $42,743.68 | 2020-2023 | Dynanail Helix, Washer, 15 Mm, Dynaclip Bone Fixation System, Quattro, 22mm X 20mm X 20mm |
| Stryker Corporation | $21,651.52 | 2019-2025 | Infinity, Prophecy, Prostep |
| Metric Medical Devices, INC. | $5,648.00 | 2022 | |
| Biotissue Holdings INC. | $737.88 | 2021-2024 | |
| Smith+Nephew, INC. | $721.89 | 2019-2025 | Stravix, Grafix Pl, Stravix Pl |
| Zimmer Biomet Holdings, INC. | $326.54 | 2021-2023 | Subchondroplasty Knee Kit, Allograft, Tapestry |
| Orthofix Medical, INC. | $325.49 | 2019-2025 | Physio-Stim |
| Treace Medical Concepts, INC. | $260.78 | 2022-2025 | |
| Wright Medical Technology, INC. | $132.12 | 2019 | |
| Linvatec Corporation | $117.77 | 2023 | Neospan Superelastic Compression Staple W/Instruments, Size 10x10x10, Colink Vallux, Rts Flexible 1st Mpj Implant W/Grommets |
| Accufix Surgical INC. | $116.16 | 2022 | |
| Kerecis Limited | $83.22 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Musculoskeletal Transplant Foundation INC. | $79.72 | 2020-2021 | |
| Integra Lifesciences Corporation | $60.21 | 2019-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Paratek Pharmaceuticals, INC. | $54.96 | 2024 | Nuzyra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifenet Health | $52.20 | 2024-2025 | Theragenesis Wound Matrix |
| Kuros Biosciences USA, INC | $50.72 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $45.45 | 2023 | Seglentis |
| Organogenesis INC. | $44.89 | 2023-2025 | Puraply, Affinity |
| Nevro Corp. | $44.50 | 2021-2022 | |
| Bone Support INC. | $43.58 | 2022 | |
| Misonix INC | $35.41 | 2021 | |
| Bioventus LLC | $29.59 | 2021-2022 | |
| Dynasplint Systems INC. | $22.29 | 2022 | |
| Convatec INC. | $21.36 | 2023 | |
| Davol INC. | $20.93 | 2021 | |
| Grt US Holding, INC. | $19.79 | 2022 | |
| Abbott Laboratories | $19.24 | 2022 | |
| Triad Life Sciences INC. | $18.63 | 2022 | |
| Kci USA, INC. | $17.43 | 2022 | |
| Osiris Therapeutics INC. | $15.64 | 2019 | |
| Horizon Therapeutics Plc | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Glod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.